Lung cancer stem cells: A biological and clinical perspective

Cellular Oncology

Volumn 36, Issue 4, 2013, Pages 265-275

  Koren, Ana ^a   Motaln, Helena ^b   Cufer, Tanja ^a  

^a UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

^b NATIONAL INSTITUTE OF BIOLOGY   (Slovenia)

Author keywords

Cancer stem cell; Circulating cancer stem cell; Clinical application; Epithelial mesenchymal transition; Lung cancer; Prognostic significance

Indexed keywords

ALDEHYDE DEHYDROGENASE; BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; CD133 ANTIGEN; CELL MARKER; CISPLATIN; DEMCIZUMAB; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEFITINIB; HERMES ANTIGEN; OMP 21M 18; PEMETREXED; TARIQUIDAR; UNCLASSIFIED DRUG;

ANGIOGENESIS; BRONCHIOLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CARCINOGENICITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL RENEWAL; CELL SUBPOPULATION; CIRCULATING TUMOR CELL; CIRCULATION; DISEASE FREE SURVIVAL; DISEASE MARKER; EMBRYONIC STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; FLUORESCENCE ACTIVATED CELL SORTING; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LONG TERM CARE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; METASTASIS; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROGENY; PROGRESSION FREE SURVIVAL; REVIEW; SECRETORY CELL; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 84881638389     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-013-0141-9     Document Type: Review

References (113)

1. A. Jemal, F. Bray, J. Ferlay, Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011)
2. T. Cufer, T. Ovcaricek, M.E.R. O'Brien, Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. Eur. J. Cancer 49, 1216-1225 (2012)
3. L.G. Collins, C. Haines, R. Perkel, R.E. Enck, Lung cancer: diagnosis, staging, and management. Am. Fam. Physician 75, 56-63 (2007)
4. W.R. Otto, Lung epithelial stem cells. J. Pathol. 197, 527-535 (2002)
5. A. Giangreco, K.R. Groot, S.M. Janes, Lung cancer and lung stem cells - Strange bedfellows? Am. J. Respir. Crit. Care Med. 175, 547-553 (2007)
6. T. Reya, S.J. Morrison, M.F. Clarke, I.L. Weissman, Stem cells, cancer, and cancer stem cells. Nature. 414, 105-111 (2001)
7. C.F.B. Kim, E.L. Jackson, A.E. Woolfenden, S. Lawrence, I. Babar, S. Vogel et al., Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121, 823-835 (2005)
8. W. Liu, N. You, N. Zhang, H. Yan, T. Wang, Z. Huang et al., Interpretation of interlocking key issues of cancer stem cells in malignant solid tumors. Cell. Oncol. 35, 397-409 (2012)
9. R. Pardal, M.F. Clarke, S.J. Morrison, Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer 3, 895-902 (2003)
10. J.P. Sullivan, J.D. Minna, J.W. Shay, Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev. 29, 61-72 (2010)
11. M.M. Gottesman, T. Fojo, S.E. Bates, Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58 (2002)
12. L. Knez, M. Košnik, T. Ovčariček, A. Sadikov, E. Sodja, I. Kern et al., Predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype in small cell lung cancer patients treated with chemotherapy. J. Cancer Res. Clin. Oncol. 138, 1551-1560 (2012)
13. S. Bao, Q. Wu, R.E. McLendon, Y. Hao, Q. Shi, A.B. Hjelmeland et al., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760 (2006)
14. J.L. Dembinski, S. Krauss, Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin. Exp. Metastasis 26, 611-623 (2009)
15. J.E. Visvader, G.J. Lindeman, Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755-768 (2008)
16. T. Lapidot, C. Sirard, J. Vormoor, B. Murdoch, T. Hoang, J. Caceres-Cortes et al., A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 367, 645-648 (1994)
17. D. Bonnet, J.E. Dick, Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737 (1997)
18. D. Ponti, A. Costa, N. Zaffaroni, G. Pratesi, G. Petrangolini, D. Coradini et al., Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 65, 5506-5511 (2005)
19. S.K. Singh, I.D. Clarke, M. Terasaki, V.E. Bonn, C. Hawkins, J. Squire et al., Identification of a cancer stem cell in human brain. Cancer Res. 63, 5821-5828 (2003)
20. A. Eramo, F. Lotti, G. Sette, E. Pilozzi, M. Biffoni, A. Di Virgilio et al., Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15, 504-514 (2008)
21. A.T. Collins, P.A. Berry, C. Hyde, M.J. Stower, N.J. Maitland, Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 65, 10946-10951 (2005)
22. L. Ricci-Vitiani, D.G. Lombardi, E. Pilozzi, M. Biffoni, M. Todaro, C. Peschle et al., Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111-115 (2007)
23. D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011)
24. C. Wu, B.A. Alman, Side population cells in human cancers. Cancer Lett. 268, 1-9 (2008)
25. S. Zhou, J.D. Schuetz, K.D. Bunting, A.M. Colapietro, J. Sampath, J.J. Morris et al., The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 7, 1028-1034 (2001)
26. D. Mizrak, M. Brittan, M.R. Alison, CD133: molecule of the moment. J. Pathol. 214, 3-9 (2008)
27. B. Jackson, C. Brocker, D.C. Thompson, W. Black, K. Vasiliou, D.W. Nebert et al., Update on the aldehyde dehydrogenase gene (ALDH) superfamily. Hum. Genomics 5, 283-303 (2011)
28. R. Stern, Association between cancer and "acid mucopolysaccharides": an old concept comes of age, finally. Semin. Cancer Biol. 18, 238-243 (2008)
29. M.M. Ho, A.V. Ng, S. Lam, J.Y. Hung, Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 67, 4827-4833 (2007)
30. C.D. Salcido, A. Larochelle, B.J. Taylor, C.E. Dunbar, L. Varticovski, Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br. J. Cancer 102, 1636-1644 (2010)
31. V. Levina, A.M. Marrangoni, R. DeMarco, E. Gorelik, A.E. Lokshin, Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 3, e3077 (2008)
32. Y.-P. Liu, C.-J. Yang, M.-S. Huang, C.-T. Yeh, A.T.H. Wu, Y.-C. Lee et al., Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. Cancer Res. 73, 406-416 (2013)
33. K. Shien, S. Toyooka, H. Yamamoto, J. Soh, M. Jida, K.L. Thu et al., Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res. 73, 3051-3061 (2013)
34. G. Bertolini, L. Roz, P. Perego, M. Tortoreto, E. Fontanella, L. Gatti et al., Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. 106, 16281-16286 (2009)
35. W. Hilbe, CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J. Clin. Pathol. 57, 965-969 (2004)
36. Y.-C. Chen, H.-S. Hsu, Y.-W. Chen, T.-H. Tsai, C.-K. How, C.-Y. Wang et al., Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 3, e2637 (2008)
37. J.S. Moreb, J.R. Zucali, B. Ostmark, N.A. Benson, Heterogeneity of aldehyde dehydrogenase expression in lung cancer cell lines is revealed by Aldefluor flow cytometry-based assay. Cytometry B Clin. Cytom. 289, 281-289 (2007)
38. F. Jiang, Q. Qiu, A. Khanna, N.W. Todd, J. Deepak, L. Xing et al., Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 7, 330-338 (2009)
39. D. Ucar, C.R. Cogle, J.R. Zucali, B. Ostmark, E.W. Scott, R. Zori et al., Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem. Biol. Interact. 178, 48-55 (2009)
40. J.P. Sullivan, M. Spinola, M. Dodge, M.G. Raso, C. Behrens, B. Gao et al., Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 70, 9937-9948 (2010)
41. E.L.-H. Leung, R.R. Fiscus, J.W. Tung, V.P.-C. Tin, L.C. Cheng, A.D.-L. Sihoe et al., Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One 5, e14062 (2010)
42. S. Akunuru, Q. James Zhai, Y. Zheng, Non-small cell lung cancer stem/ progenitor cells are enriched in multiple distinct phenotypic subpopulations and exhibit plasticity. Cell Death Dis. 3, e352 (2012)
43. X. Meng, X. Wang, Y. Wang, More than 45 % of A549 and H446 cells are cancer initiating cells: evidence from cloning and tumorigenic analyses. Oncol. Rep. 21, 995-1000 (2009)
44. G.P. Kalemkerian, Advances in the treatment of small-cell lung cancer. Semin. Respir. Crit. Care Med. 32, 94-101 (2011)
45. K. Hotta, K. Kiura, Y. Fujiwara, N. Takigawa, I. Oze, N. Ochi et al., Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer. Ann. Oncol. 20, 829-834 (2009)
46. Z.A. Rasheed, J. Kowalski, B.D. Smith, W. Matsui, Concise review: emerging concepts in clinical targeting of cancer stem cells. Stem Cells 29, 883-887 (2011)
47. W.C.-S. Cho, Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Biomed. Pharmacother. 61, 515-519 (2007)
48. J.A. Ludwig, J.N. Weinstein, Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5, 845-856 (2005)
49. A.V. Salnikov, J. Gladkich, G. Moldenhauer, M. Volm, J. Mattern, I. Herr, CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int. J. Cancer 126, 950-958 (2010)
50. T. Woo, K. Okudela, H. Mitsui, T. Yazawa, N. Ogawa, M. Tajiri et al., Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int. J. Clin. Exp. Pathol. 4, 32-42 (2010)
51. Li, H. Zeng, K. Ying, The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas. Med. Oncol. 28, 1458-1462 (2011)
52. E. Herpel, K. Jensen, T. Muley, A. Warth, P.A. Schnabel, M. Meister et al., The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer. Anticancer. Res. 31, 4491-4500 (2011)
53. K. Vrzalikova, J. Skarda, J. Ehrmann, P.G. Murray, E. Fridman, J. Kopolovic et al., Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J. Cancer Res. Clin. Oncol. 134, 1037-1042 (2008)
54. J. Kikuchi, I. Kinoshita, Y. Shimizu, E. Kikuchi, J. Konishi, S. Oizumi et al., Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer 116, 3015-3024 (2010)
55. K. Shien, S. Toyooka, K. Ichimura, J. Soh, M. Furukawa, Y. Maki et al., Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer 7, 162-167 (2012)
56. P. Micke, M. Basrai, A. Faldum, F. Bittinger, L. Rönnstrand, A. Blaukat et al., Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin. Cancer Res. 9, 188-194 (2003)
57. X. Zhang, B. Han, J. Huang, B. Zheng, Q. Geng, F. Aziz et al., Prognostic significance of OCT4 expression in adenocarcinoma of the lung. Jpn. J. Clin. Oncol. 40, 961-966 (2010)
58. X. Li, J. Wang, Z. Xu, A. Ahmad, E. Li, Y. Wang et al., Expression of sox2 and oct4 and their clinical significance in human non-small-cell lung cancer. Int. J. Mol. Sci. 13, 7663-7675 (2012)
59. L. Cortes-Dericks, D. Galetta, L. Spaggiari, R.A. Schmid, G. Karoubi, High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals. Eur. J. Cardiothorac. Surg. 41, e173-e181 (2012)
60. F. Zeppernick, R. Ahmadi, B. Campos, C. Dictus, B.M. Helmke, N. Becker et al., Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 14, 123-129 (2008)
61. W. Song, H. Li, K. Tao, R. Li, Z. Song, Q. Zhao et al., Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int. J. Clin. Pract. 62, 1212-1218 (2008)
62. T. Li, Y. Su, Y. Mei, Q. Leng, B. Leng, Z. Liu et al., ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Investig. 90, 234-244 (2010)
63. C. Ginestier, M.H. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, M. Brown et al., ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567 (2007)
64. B. Chang, G. Liu, F. Xue, D.G. Rosen, L. Xiao, X. Wang et al., ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod. Pathol. 22, 817-823 (2009)
65. C. Tempfer, A. Lösch, H. Heinzl, G. Häusler, E. Hanzal, H. Kölbl et al., Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer. Eur. J. Cancer 32A, 2023-2025 (1996)
66. K.-C. Wei, C.-Y. Huang, P.-Y. Chen, L.-Y. Feng, T.-W.E. Wu, S.-M. Chen et al., Evaluation of the prognostic value of CD44 in glioblastoma multiforme. Anticancer. Res. 30, 253-259 (2010)
67. J.S. Dovey, S.J. Zacharek, C.F. Kim, J.A. Lees, Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion. Proc. Natl. Acad. Sci. 105, 11857-11862 (2008)
68. K. Wu, Direct activation of Bmi1 by Twist1: implications in cancer stemness, epithelial-mesenchymal transition, and clinical significance. Chang Gung Med. J. 34, 229-238 (2011)
69. H. Wang, K. Pan, H. Zhang, D. Weng, J. Zhou, J. Li et al., Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 134, 535-541 (2008)
70. J.-H. Liu, L.-B. Song, X. Zhang, B.-H. Guo, Y. Feng, X.-X. Li et al., Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J. Surg. Oncol. 97, 267-272 (2008)
71. Y.J. Choi, Y. La Choi, E.Y. Cho, Y.K. Shin, K.W. Sung, Y.K. Hwang et al., Expression of Bmi-1 protein in tumor tissues is associated with favorable prognosis in breast cancer patients. Breast Cancer Res. Treat. 113, 83-93 (2009)
72. K. Takahashi, K. Tanabe, M. Ohnuki, M. Narita, T. Ichisaka, K. Tomoda et al., Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872 (2007)
73. M. Field, A. Alvarez, S. Bushnev, K. Sugaya, Embryonic stem cell markers distinguishing cancer stem cells from normal human neuronal stem cell populations in malignant glioma patients. Clin. Neurosurg. 57, 151-159 (2010)
74. S.-H. Chiou, M.-L. Wang, Y.-T. Chou, C.-J. Chen, C.-F. Hong, W.-J. Hsieh et al., Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 70, 10433-10444 (2010)
75. J. Taipale, P.A. Beachy, The Hedgehog and Wnt signalling pathways in cancer. Nature 411, 349-354 (2001)
76. P. Polakis, Wnt signaling and cancer Wnt signaling and cancer. Genes Dev. 14, 1837-1851 (2000)
77. L. Jiang, J. Li, L. Song, Bmi-1, stem cells and cancer. Acta Biochim. Biophys. Sin. (Shanghai) 41, 527-534 (2009)
78. M.R. García Campelo, G. Alonso Curbera, G. Aparicio Gallego, E. Grande Pulido, L.M. Antón Aparicio, Stem cell and lung cancer development: blaming the Wnt, Hh and Notch signalling pathway. Clin. Transl. Oncol. 13, 77-83 (2011)
79. J. Vestergaard, M.W. Pedersen, N. Pedersen, C. Ensinger, Z. Tümer, N. Tommerup et al., Hedgehog signaling in small-cell lung cancer: frequent in vivo but a rare event in vitro. Lung Cancer 52, 281-290 (2006)
80. D.N. Watkins, D.M. Berman, S.G. Burkholder, B. Wang, P.A. Beachy, S.B. Baylin, Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 422, 313-317 (2003)
81. L. You, B. He, Z. Xu, K. Uematsu, J. Mazieres, I. Mikami et al., Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene 23, 6170-6174 (2004)
82. V. Levina, A. Marrangoni, T. Wang, S. Parikh, Y. Su, R. Herberman et al., Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res. 70, 338-346 (2010)
83. T. Hu, S. Liu, D.R. Breiter, F. Wang, Y. Tang, S. Sun, Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res. 68, 6533-6540 (2008)
84. A. Eramo, T.L. Haas, R. De Maria, Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene 29, 4625-4635 (2010)
85. R.J. Kelly, D. Draper, C.C. Chen, R.W. Robey, W.D. Figg, R.L. Piekarz et al., A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin. Cancer Res. 17, 569-580 (2011)
86. A. Singh, J. Settleman, EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741-4751 (2010)
87. J.P. Thiery, J.P. Sleeman, Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7, 131-142 (2006)
88. M. Guarino, B. Rubino, G. Ballabio, The role of epithelial-mesenchymal transition in cancer pathology. Pathology 39, 305-318 (2008)
89. J.P. Thiery, H. Acloque, R.Y.J. Huang, M.A. Nieto, Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890 (2009)
90. J. Thiery, Epithelial-mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol. 15, 740-746 (2003)
91. S.A. Mani, W. Guo, M.-J. Liao, E.N. Eaton, A. Ayyanan, A.Y. Zhou et al., The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008)
92. A.-P. Morel, M. Lièvre, C. Thomas, G. Hinkal, S. Ansieau, A. Puisieux, Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3, e2888 (2008)
93. V.L. Battula, K.W. Evans, B.G. Hollier, Y. Shi, F.C. Marini, A. Ayyanan et al., Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells 28, 1435-1445 (2010)
94. J.K. Rho, Y.J. Choi, J.K. Lee, B.-Y. Ryoo, I. Il Na, S.H. Yang et al., Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 63, 219-226 (2009)
95. K. Suda, K. Tomizawa, M. Fujii, H. Murakami, H. Osada, Y. Maehara et al., Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J. Thorac. Oncol. 6, 1152-1161 (2011)
96. F. Nurwidya, F. Takahashi, A. Murakami, K. Takahashi, Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res. Treat. 44, 151-156 (2012)
97. T. Ashworth, A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust. Med. J. 14, 146-147 (1869)
98. W.J. Allard, J. Matera, M.C. Miller, M. Repollet, M.C. Connelly, C. Rao et al., Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10, 6897-6904 (2004)
99. M. Alunni-Fabbroni, M.T. Sandri, Circulating tumour cells in clinical practice: methods of detection and possible characterization. Methods 50, 289-297 (2010)
100. B. Kubuschok, B. Passlick, J.R. Izbicki, O. Thetter, K. Pantel, Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J. Clin. Oncol. 17, 19-24 (1999)
101. T.J.N. Hiltermann, M.M. Pore, A. Van Den Berg, W. Timens, H.M. Boezen, J.J.W. Liesker et al., Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann. Oncol. 23, 2937-2942 (2012)
102. V. Hofman, M.I. Ilie, E. Long, E. Selva, C. Bonnetaud, T. Molina et al., Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the Cell Search AssayTM and the isolation by size of epithelial tumor cell method. Int. J. Cancer 129, 1651-1660 (2011)
103. V. Hofman, C. Bonnetaud, M.I. Ilie, P. Vielh, J.M. Vignaud, J.F. Fléjou et al., Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin. Cancer Res. 17, 827-835 (2011)
104. M.G. Krebs, J.-M. Hou, R. Sloane, L. Lancashire, L. Priest, D. Nonaka et al., Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J. Thorac. Oncol. 7, 306-315 (2011)
105. A. Rolle, R. Günzel, U. Pachmann, B. Willen, K. Höffken, K. Pachmann, Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(R) is a predictor for relapse: a preliminary report. World J. Surg. Oncol. 3, 18 (2005)
106. Y.-F. Sun, X.-R. Yang, J. Zhou, S.-J. Qiu, J. Fan, Y. Xu, Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J. Cancer Res. Clin. Oncol. 137, 1151-1173 (2011)
107. M. Yu, A. Bardia, B.S. Wittner, S.L. Stott, M.E. Smas, D.T. Ting et al., Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580-584 (2013)
108. A. Gradilone, C. Raimondi, C. Nicolazzo, A. Petracca, O. Gandini, B. Vincenzi et al., Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. J. Cell Mol. Med. 15, 1066-1070 (2011)
109. M. Balic, H. Lin, L. Young, D. Hawes, A. Giuliano, G. McNamara et al., Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12, 5615-5621 (2006)
110. Z.F. Yang, P. Ngai, D.W. Ho, W.C. Yu, M.N.P. Ng, C.K. Lau et al., Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 47, 919-928 (2008)
111. P.A. Theodoropoulos, H. Polioudaki, S. Agelaki, G. Kallergi, Z. Saridaki, D. Mavroudis et al., Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 288, 99-106 (2010)
112. N. Mehra, M. Penning, J. Maas, L.V. Beerepoot, N. van Daal, C.H. van Gils et al., Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clin. Cancer Res. 12, 4859-4866 (2006)
113. T. Brabletz, A. Jung, S. Spaderna, F. Hlubek, T. Kirchner, Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. Cancer 5, 744-749 (2005)